{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T21:09:42Z","timestamp":1786482582154,"version":"build-2736575974"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T00:00:00Z","timestamp":1687910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T00:00:00Z","timestamp":1687910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Bispecific antibodies are emerging as a promising new immunotherapy modality and are actively being evaluated in clinical trials for patients with lymphoma. As the first BsAb to receive regulatory approval for lymphoma, mosunetuzumab, an antiCD20\/anti-CD3 BsAb, is an exciting new option for patients with relapsed or refractory (R\/R) follicular lymphoma. The approval was based on results from an international, multicenter, phase 2 trial in patients with relapsed or refractory (R\/R) follicular lymphoma following at least 2 prior lines of systemic therapy. Mosunetuzumab demonstrated remarkable efficacy with an overall response rate of 80% and complete response rate of 60%. Here we provided an overview of the latest clinical data on mosunetuzumab in lymphoma presented at the 2022 ASH Annual Meeting.<\/jats:p>","DOI":"10.1186\/s13045-023-01462-0","type":"journal-article","created":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T17:02:13Z","timestamp":1687971733000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Mosunetuzumab and lymphoma: latest updates from 2022 ASH annual meeting"],"prefix":"10.1186","volume":"16","author":[{"given":"Yang","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela C.","family":"Marcucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua E.","family":"Budde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,28]]},"reference":[{"issue":"Supplement 1","key":"1462_CR1","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1182\/blood-2022-157691","volume":"140","author":"NL Bartlett","year":"2022","unstructured":"Bartlett NL, Sehn LH, Matasar MJ, Schuster SJ, Assouline SE, Giri P, et al. Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed\/refractory follicular lymphoma who received \u22652 prior therapies: updated results from a pivotal phase II study. Blood. 2022;140(Supplement 1):1467\u201370.","journal-title":"Blood"},{"issue":"8","key":"1462_CR2","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","volume":"23","author":"LE Budde","year":"2022","unstructured":"Budde LE, Sehn LH, Matasar M, Schuster SJ, Assouline SE, Giri P, et al. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022;23(8):1055\u201365.","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"1462_CR3","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.1182\/blood-2022-159640","volume":"140","author":"SF McGough","year":"2022","unstructured":"McGough SF, Shamas N, Wang J, Jaber M, Swarup B, Zumofen MB, et al. An external control for mosunetuzumab using real-world data in follicular lymphoma in the third or subsequent lines of systemic therapy. Blood. 2022;140(Supplement 1):3658\u201360.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1462_CR4","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1182\/blood-2022-157729","volume":"140","author":"LE Budde","year":"2022","unstructured":"Budde LE, Bartlett NL, Giri P, Schuster SJ, Assouline SE, Yoon S, et al. Subcutaneous Mosunetuzumab is active with a manageable safety profile in patients (pts) with relapsed\/refractory (R\/R) B-cell non-hodgkin lymphomas (B-NHLs): updated results from a phase I\/II study. Blood. 2022;140(Supplement 1):3753\u20135.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1462_CR5","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1182\/blood-2022-157768","volume":"140","author":"AJ Olszewski","year":"2022","unstructured":"Olszewski AJ, Avigdor A, Babu S, Levi I, Eradat H, Abadi U, et al. Mosunetuzumab monotherapy continues to demonstrate promising efficacy and durable complete responses in elderly\/unfit patients with previously untreated diffuse large B-cell lymphoma. Blood. 2022;140(Supplement 1):1778\u201380.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1462_CR6","doi-asserted-by":"publisher","first-page":"3757","DOI":"10.1182\/blood-2022-159594","volume":"140","author":"AJ Olszewski","year":"2022","unstructured":"Olszewski AJ, Budde LE, Chavez J, Ghosh N, Kamdar M, Lossos IS, et al. Mosunetuzumab with polatuzumab vedotin is effective and has a manageable safety profile in patients aged <65 and \u226565 years with relapsed\/refractory diffuse large B-cell lymphoma (R\/R DLBCL) and \u22651 prior therapy: subgroup analysis of a phase Ib\/II study. Blood. 2022;140(Supplement 1):3757\u20139.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1462_CR7","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1182\/blood-2022-157710","volume":"140","author":"J Westin","year":"2022","unstructured":"Westin J, Olszewski AJ, Fogliatto LM, Kim W, Shin H, Wu H, et al. SUNMO: a phase III trial evaluating the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin versus rituximab in combination with gemcitabine plus oxaliplatin in patients with relapsed or refractory aggressive B-cell non-hodgkin lymphoma. Blood. 2022;140(Supplement 1):3771\u20132.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1462_CR8","doi-asserted-by":"publisher","first-page":"6492","DOI":"10.1182\/blood-2022-157463","volume":"140","author":"AJ Olszewski","year":"2022","unstructured":"Olszewski AJ, Huntington SF, Bannerji R, Ollila TA, McMahon J, Dubielecka PM. Mosunetuzumab with lenalidomide augmentation as first-line therapy for follicular (FL) and marginal zone lymphoma (MZL). Blood. 2022;140(Supplement 1):6492\u20133.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1462_CR9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1182\/blood-2021-145694","volume":"138","author":"F Morschhauser","year":"2021","unstructured":"Morschhauser F, Bishton M, Eyre TA, Bachy E, Cartron G, Ysebaert L, et al. Mosunetuzumab in combination with lenalidomide has a manageable safety profile and encouraging activity in patients with relapsed\/refractory follicular lymphoma: initial results from a phase Ib study. Blood. 2021;138(Supplement 1):129.","journal-title":"Blood"},{"issue":"Supplement 1","key":"1462_CR10","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1182\/blood-2022-157256","volume":"140","author":"M Bishton","year":"2022","unstructured":"Bishton M, Woestmann C, Morschhauser F, Eyre TA, Shin M, Schroeder A, et al. Analysis of immune pharmacodynamic and baseline biomarkers in patients with relapsed or refractory follicular lymphoma treated with mosunetuzumab in combination with lenalidomide. Blood. 2022;140(Supplement 1):3555\u20136.","journal-title":"Blood"},{"issue":"16_suppl","key":"1462_CR11","doi-asserted-by":"publisher","first-page":"7526","DOI":"10.1200\/JCO.2022.40.16_suppl.7526","volume":"40","author":"SJ Schuster","year":"2022","unstructured":"Schuster SJ, Huw L, Bolen CR, Assouline SE, Bartlett NL, Budde LE, et al. Characterization of CD20 expression loss as a mechanism of resistance to mosunetuzumab in patients with relapsed\/refractory B-cell non-Hodgkin lymphomas. J Clinic Oncol. 2022;40(16_suppl):7526.","journal-title":"J Clinic Oncol"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-023-01462-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-023-01462-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-023-01462-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T17:02:48Z","timestamp":1689267768000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-023-01462-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,28]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1462"],"URL":"https:\/\/doi.org\/10.1186\/s13045-023-01462-0","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,28]]},"assertion":[{"value":"27 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LEB has received research funding support and consultancy fee from Genentech Inc, Merck, AstraZeneca, Amgen, and Mustang Therapeutics. YC and EM have no relevant conflicts.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This is not applicable for this summary.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This is not applicable for this summary.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LEB has received research funding support and consultancy fee from Genentech Inc, Merck, AstraZeneca, Amgen, and Mustang Therapeutics. YC and EM have no relevant conflicts.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"69"}}